A novel gas chromatography mass spectrometry-based serum diagnostic and assessment approach to ulcerative colitis

Journal of Crohn's and Colitis

Volumn 8, Issue 9, 2014, Pages 1010-1021

  Kohashi, Michitaka ^a   Nishiumi, Shin ^a   Ooi, Makoto ^a   Yoshie, Tomoo ^a   Matsubara, Atsuki ^a   Suzuki, Makoto ^a   Hoshi, Namiko ^a   Kamikozuru, Koji ^b   Yokoyama, Yoko ^b   Fukunaga, Ken ^b   Nakamura, Shiro ^b   Azuma, Takeshi ^a   Yoshida, Masaru ^a  

^a KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b HYOGO COLLEGE OF MEDICINE   (Japan)

Author keywords

Biomarker; GC MS; Metabolomics; Multiple logistic regression analysis; Ulcerative colitis

Indexed keywords

ADULT; ARTICLE; CLINICAL ASSESSMENT; CONTROLLED STUDY; CROHN DISEASE; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE ACTIVITY; DISEASE COURSE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MASS FRAGMENTOGRAPHY; METABOLOMICS; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; ULCERATIVE COLITIS; ADOLESCENT; AGED; BLOOD; CHILD; CLINICAL TRIAL; COLITIS, ULCERATIVE; FOLLOW UP; MIDDLE AGED; MULTICENTER STUDY; PROCEDURES; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; RECEIVER OPERATING CHARACTERISTIC; REPRODUCIBILITY; RETROSPECTIVE STUDY; YOUNG ADULT; DIAGNOSTIC APPROACH ROUTE; GAS CHROMATOGRAPHY; MASS SPECTROMETRY;

BIOLOGICAL MARKER;

ADOLESCENT; ADULT; AGED; BIOLOGICAL MARKERS; CHILD; COLITIS, ULCERATIVE; FEMALE; FOLLOW-UP STUDIES; GAS CHROMATOGRAPHY-MASS SPECTROMETRY; HUMANS; MALE; METABOLOMICS; MIDDLE AGED; PROGNOSIS; REPRODUCIBILITY OF RESULTS; RETROSPECTIVE STUDIES; ROC CURVE; YOUNG ADULT;

EID: 84906791098     PISSN: 18739946     EISSN: 18764479     Source Type: Journal    
DOI: 10.1016/j.crohns.2014.01.024     Document Type: Article

References (54)

1. Prideaux L., Kamm M.A., De Cruz P.P., Chan F.K., Ng S.C. Inflammatory bowel disease in Asia: a systematic review. J Gastroenterol Hepatol 2012, 27(8):1266-1280.
2. Xavier R.J., Podolsky D.K. Unravelling the pathogenesis of inflammatory bowel disease. Nature 2007, 26(448(7152)):427-434.
3. Kaser A., Zeissig S., Blumberg R.S. Inflammatory bowel disease. Annu Rev Immunol 2010, 28:573-621.
4. Tysk C., Lindberg E., Järnerot G., Flodérus-Myrhed B. Ulcerative colitis and Crohn's disease in an unselected population of monozygotic and dizygotic twins. A study of heritability and the influence of smoking. Gut 1988, 29(7):990-996.
5. Orholm M., Munkholm P., Langholz E., Nielsen O.H., Sørensen T.I., Binder V. Familial occurrence of inflammatory bowel disease. N Engl J Med 1991, 324(2):84-88.
6. Price A.B. Overlap in the spectrum of non-specific inflammatory bowel disease-'colitis indeterminate'. J Clin Pathol 1978, 31(6):567-577.
7. Koltun W.A., Schoetz D.J., Roberts P.L., Murray J.J., Coller J.A., Veidenheimer M.C. Indeterminate colitis predisposes to perineal complications after ileal pouch-anal anastomosis. Dis Colon Rectum 1991, 34(10):857-860.
8. Moum B., Ekboum A., Vatn M.H., Aadland E., Sauar J., Lygren I., et al. Inflammatory bowel disease: re-evaluation of the diagnosis in a prospective population based study in southeastern Norway. Gut 1997, 40:328-332.
9. Reese G.E., Constantinides V.A., Simillis C., Darzi A.W., Orchard T.R., Fazio V.W., et al. Diagnostic precision of anti-Saccharomyces cerevisiae antibodies and perinuclear antineutrophil cytoplasmic antibodies in inflammatory bowel disease. Am J Gastroenterol 2006, 101(10):2410-2422.
10. Schicho R., Shaykhutdinov R., Nqo J., Nazyrova A., Schneider C., Panaccione R., et al. Quantitative metabolomic profiling of serum, plasma, and urine by (1)H NMR spectroscopy discriminates between patients with inflammatory bowel disease and healthy individuals. J Proteome Res 2012, 11(6):3344-3357.
11. Meuwis M.A., Fillet M., Geurts P., de Seny D., Lutteri L., Chapelle J.P., et al. Biomarker discovery for inflammatory bowel disease, using proteomic serum profiling. Biochem Pharmacol 2007, 73(9):1422-1433.
12. Nanni P., Parisi D., Roda G., Casale M., Belluzzi A., Roda E., et al. Serum protein profiling in patients with inflammatory bowel diseases using selective solid-phase bulk extraction, matrix-assisted laser desorption/ionization time-of-flight mass spectrometry and chemometric data analysis. Rapid Commun Mass Spectrom 2007, 21(24):4142-4148.
13. Yoshida M., Hatano N., Nishiumi S., Irino Y., Izumi Y., Takenawa T., et al. Diagnosis of gastroenterological diseases by metabolome analysis using gas chromatography-mass spectrometry. J Gastroenterol 2012, 47:9-20.
14. Lin H.M., Barnett M.P., Roy N.C., Joyce N.I., Zhu S., Armstrong K., et al. Metabolomic analysis identifies inflammatory and noninflammatory metabolic effects of genetic modification in a mouse model of Crohn's disease. J Proteome Res 2010, 9(4):1965-1975.
15. Shiomi Y., Nishiumi S., Ooi M., Hatano N., Shinohara M., Yoshie T., et al. GCMS-based metabolomic study in mice with colitis induced by dextran sulfate sodium. Inflamm Bowel Dis 2011, 17:2261-2274.
16. Ooi M., Nishiumi S., Yoshie T., Shiomi Y., Kohashi M., Fukunaga K., et al. GC/MS-based profiling of amino acids and TCA cycle-related molecules in ulcerative colitis. Inflamm Res 2011, 60:831-840.
17. Winship D.H., Summers R.W., Singleton J.W., Best W.R., Becktel J.M., Lenk L.F., et al. National Cooperative Crohn's Disease Study: study design and conduct of the study. Gastroenterology 1979, 77(4 Pt 2):829-842.
18. Rachmilewitz D. Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomised trial. BMJ 1989, 298(6666):82-86.
19. Nishiumi S., Kobayashi T., Ikeda A., Yoshie T., Kibi M., Izumi Y., et al. A novel serum metabolomics-based diagnostic approach for colorectal cancer. PLoS One 2012, 7(7):e40459.
20. Tsugawa H., Bamba T., Shinohara M., Shinohara M., Nishiumi S., Yoshida M., et al. Practical non-targeted gas chromatography/mass spectrometry-based metabolomics platform for metabolic phenotype analysis. J Biosci Bioeng 2011, 112(3):292-298.
21. Tsugawa H., Tsujimoto Y., Arita M., Bamba T., Fukusaki E. GC/MS based metabolomics: development of a data mining system for metabolite identification by using soft independent modeling of class analogy (SIMCA). BMC Bioinformatics 2011, 12:131.
22. Cui X., Churchill G.A. Statistical tests for differential expression in cDNA microarray experiments. Genome Biol 2003, 4(4):210.
23. Kobayashi T., Nishiumi S., Ikeda A., Yoshie T., Sakai A., Matsubara A., et al. A novel serum metabolomics-based diagnostic approach to pancreatic cancer. Cancer Epidemiol Biomarkers Prev 2013, 22(4):571-579.
24. Peyrine-Biroulet L., Standaert-Vitse A., Branche J., Chamaillard M. IBD serological panels: facts and perspectives. Inflamm Bowel Dis 2007, 13(12):1561-1566.
25. Papp M., Norman G.L., Altorjay I., Lakatos P.L. Utility of serological markers in inflammatory bowel diseases: gadget or magic?. World J Gastroenterol 2007, 13(14):2028-2036.
26. Nakamura R.M., Matsutani M., Barry M. Advances in clinical laboratory tests for inflammatory bowel disease. Clin Chim Acta 2003, 335(1-2):9-20.
27. Landers C.J., Cohavy O., Misra R., Yang H., Lin Y.C., Braun J., et al. Selected loss of tolerance evidenced by Crohn's disease-associated immune responses to auto- and microbial antigens. Gastroenterology 2002, 123(3):689-699.
28. Sutton C.L., Kim J., Yamane A., Dalwadi H., Wei B., Landers C., et al. Identification of a novel bacterial sequence associated with Crohn's disease. Gastroenterology 2000, 119(1):23-31.
29. Lodes M.J., Cong Y., Elson C.O., Mohamath R., Landers C.J., Targan S.R., et al. Bacterial flagellin is a dominant antigen in Crohn disease. J Clin Invest 2004, 113(9):1296-1306.
30. Targan S.R., Landers C.J., Yang H., Lodes M.J., Cong Y., Papadakis K.A., et al. Antibodies to CBir1 flagellin define a unique response that is associated independently with complicated Crohn's disease. Gastroenterology 2005, 128(7):2020-2028.
31. Hisamatsu T., Okamoto S., Hashimoto M., Lodes M.J., Cong Y., Papadakis K.A., et al. Novel, objective, multivariate biomarkers composed of plasma amino acid profile for diagnosis and assessment of inflammatory bowel disease. PLoS One 2012, 7(1):e31131.
32. Hanai H., Takeuchi K., Iida T., Kashiwagi N., Saniabadi A.R., Matsushita I., et al. Relationship between fecal calprotectin, intestinal inflammation, and peripheral blood neutrophils in patients with ulcerative colitis. Dig Dis Sci 2004, 49(9):1438-1443.
33. Kolho K.L., Turner D. Fecal calprotectin and clinical disease activity in pediatric ulcerative colitis. ISRN Gastroenterology 2013, 2013:179024.
34. D'Incà R., Dal Pont E., Di Leo V., Ferronato A., Fries W., Vettorato M.G., et al. Calprotectin and lactoferrin in the assessment of intestinal inflammation and organic disease. Int J Colorectal Dis 2007, 22(4):429-437.
35. Schoepfer A.M., Beglinger C., Straumann A., Trummler M., Renzulli P., Seibold F. Ulcerative colitis: correlation of the Rachmilewitz endoscopic activity index with fecal calprotectin, clinical activity, C-reactive protein, and blood leukocytes. Inflamm Bowel Dis 2009, 15(12):1851-1858.
36. Hotchkiss R.S., Karl I.E. Reevaluation of the role of cellular hypoxia and bioenergetic failure in sepsis. JAMA 1992, 267(11):1503-1510.
37. Wolfe R.R., Jahoor F., Herndon D.N., Miyoshi H. Isotopic evaluation of the metabolism of pyruvate and related substrates in normal adult volunteers and severely burned children: effect of dichloroacetate and glucose infusion. Surgery 1991, 110(1):54-67.
38. Lawrance I.C., Fiocchi C., Chakravarti S. Ulcerative colitis and Crohn's disease: distinctive gene expression profiles and novel susceptibility candidate genes. Hum Mol Genet 2001, 10(5):445-456.
39. Guri A.J., Mohapatra S.K., Horne W.T., Hontecillas R., Bassaganya-Riera J. The role of T cell PPAR gamma in mice with experimental inflammatory bowel disease. BMC Gastroenterol 2010, 10:60.
40. Andou A., Hisamatsu T., Okamoto S., Chinen H., Kamada N., Kobayashi T., et al. Dietary histidine ameliorates murine colitis by inhibition of proinflammatory cytokine production from macrophages. Gastroenterology 2009, 136(2):564-574. [e2].
41. Kim C.J., Kovacs-Nolan J.A., Yanq C., Archbold T., Fan M.Z., Mine Y. l-Tryptophan exhibits therapeutic function in a porcine model of dextran sodium sulfate (DSS)-induced colitis. J Nutr Biochem 2010, 21(6):468-475.
42. Ban K., Kozar R.A. Glutamine protects against apoptosis via downregulation of Sp3 in intestinal epithelial cells. Am J Physiol Gastrointest Liver Physiol 2010, 299(6):G1344-G1353.
43. Belmonte L., Coëffier M., Le Pessot F., Miralles-Barrachina O., Hiron M., Leplingard A., et al. Effects of glutamine supplementation on gut barrier, glutathione content and acute phase response in malnourished rats during inflammatory shock. World J Gastroenterol 2007, 13(20):2833-2840.
44. Munn D.H., Shafizadeh E., Attwood J.T., Bondarev I., Pashine A., Mellor A.L. Inhibition of T cell proliferation by macrophage tryptophan catabolism. J Exp Med 1999, 189(9):1363-1372.
45. Terness P., Bauer T.M., Röse L., Bondarev I., Pashine A., Mellor A.L. Inhibition of allogeneic T cell proliferation by indoleamine 2,3-dioxygenase-expressing dendritic cells: mediation of suppression by tryptophan metabolites. J Exp Med 2002, 196(4):447-457.
46. Frumento G., Rotondo R., Tonetti M., Damonte G., Benatti U., Ferrara G.B. Tryptophan-derived catabolites are responsible for inhibition of T and natural killer cell proliferation induced by indoleamine 2,3-dioxygenase. J Exp Med 2002, 196(4):459-468.
47. Zhou L., Chen H., Wen Q., Zhang Y. Indoleamine 2,3-dioxygenase expression in human inflammatory bowel disease. Eur J Gastroenterol Hepatol 2012, 24(6):695-701.
48. Zezos P., Papaioannou G., Nikolaidis N., Vasiliadis T., Giouleme O., Evgenidis N. Hyperhomocysteinemia in ulcerative colitis is related to folate levels. World J Gastroenterol 2005, 11(38):6038-6042.
49. Upchurch G.R., Welch G.N., Fabian A.J., Freedman J.E., Johnson J.L., Keaney J.F., et al. Homocyst(e)ine decreases bioavailable nitric oxide by a mechanism involving glutathione peroxidase. J Biol Chem 1997, 272(27):17012-17017.
50. Mlinow M.R. Hyperhomocyst(e)inemia. A common and easily reversible risk factor for occlusive atherosclerosis. Circulation 1990, 81(6):2004-2006.
51. Talbot R.W., Heppell J., Dozois R.R., Beart R.W. Vascular complications of inflammatory bowel disease. Mayo Clin Proc 1986, 61(2):140-145.
52. Vecchi M., Cattaneo M., de Francis R., Mannucci P.M. Risk of thromboembolic complications in patients with inflammatory bowel disease. Study of hemostasis measurements. Int J Clin Lab Res 1991, 21(2):165-170.
53. Hong S.K., Maltz B.E., Coburn L.A., Slaughter J.C., Chaturvedi R., Schwartz D.A., et al. Increased serum levels of L-arginine in ulcerative colitis and correlation with disease severity. Inflamm Bowel Dis 2010 Jan, 16(1):105-111.
54. Coburn L.A., Gong X., Singh K., Asim M., Scull B.P., Allaman M.M., et al. L-arginine supplementation improves responses to injury and inflammation in dextran sulfate sodium colitis. PLoS ONE 2012, 7(3):e33546.